News
What exactly is Alzheimer’s disease, and how common is it? A: Alzheimer’s disease is a neurodegenerative disease that causes dementia. It is caused in part by the accumulation of abnormally folded ...
Eli Lilly stock currently trades below its 50-week average, offering a strong entry point despite continued dominance in ...
8dOpinion
Montreal Gazette on MSNOpinion: Canada is falling behind on treatments for Alzheimer’s diseaseUnfortunately, medical treatments for Alzheimer’s disease and dementia have remained minimal for over 25 years, and with a ...
A once-a-day pill called blarcamesine may slow memory loss and preserve independence—without the scary side effects or ...
Discover breaking news detailing why the NHS will not cover two new Alzheimer’s drugs due to the high annual costs.
Dr. Nicholas Milano of Medical University of SC says medications such as Lecanemab and donanemab give Alzheimer's patients ...
The UK’s National Institute for Health and Care Excellence (Nice) has declined to recommend two new Alzheimer’s drugs for ...
New immunotherapy drugs offer some hope in the fight against Alzheimer's disease but they're too pricey for the NHS ...
To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved Alzheimer’s disease drugs are too small to justify the costs. Neither Kisunla ...
Donanemab is given monthly, via intravenous infusion. What does the evidence say? Australia’s approval of donanemab comes as a result of a clinical trial involving 1,736 people published in 2023.
Donanemab was licensed for use in the UK last year but is still only available privately as it was not deemed to be cost-effective enough to be subsidised by the National Health System (NHS).
Donanemab, recently approved by the FDA, offers new hope for patients in the early stages of Alzheimer’s disease—slowing memory loss by up to 29% over 18 months (1 Trusted Source ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results